Subcutaneous Interferon Beta-1a Decreases the Evolution of Gadolinium-Enhancing Lesions Into Chronic Black Holes in Relapsing Multiple Sclerosis (P7.240)

CONCLUSIONS: sc IFN beta-1a was associated with a decreased proportion of new Gd+ lesions evolving into CBHs, particularly in patients with lower disability scores.Study Support: Merck Serono SA Geneva, Switzerland, a subsidiary of Merck KGaA, Darmstadt, GermanyDisclosure: Dr. Traboulsee has received personal compensation for activities with Roche Diagnostics Corp., EMD Serono, Teva Neuroscience, and Biogen Idec. Dr. Traboulsee has received research support from Bayer Pharmaceuticals Corp., and Roche Diagnostics Corp. Dr. Li has received personal compensation for activities with Opexa, Nuron, Genzyme Corp., Roche Diagnostics Corp., and Novartis. Dr. Li has received research support from EMD Serono, Genzyme Corp., and Roche Diagnostics Corp. Dr. Zhao has received personal compensation for activities with F. Hoffman-La Roche. Dr. Zhao has received research support from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, Multiple Sclerosis Society of Canada, and the Milan & Maureen Ilich Foundation. Dr. Tam has received research support from Biogen Idec. Dr. Zhao has nothing to disclose. Dr. Cheng has nothing to disclose. Dr. Riddehough has nothing to disclose. Dr. Dangond has received personal compensation for activities with EMD Serono, Inc. Dr. Fang has received personal compensation for activities with EMD Serono as an employee. Dr. Kappos has received personal compensation for activities with the University Hospital Basel. Dr. Kappos has...

Source: Neurology - April 9, 2014 Category: Neurology Authors: Traboulsee, A., Li, D., Zhao, Y., Tam, R., Zhao, G., Cheng, Y., Riddehough, A., Dangond, F., Fang, J., Kappos, L. Tags: Multiple Sclerosis and CNS Inflammatory Diseases: Treatment Source Type: research